In the following video, health care editor/analyst David Williamson discusses the recent analyst upgrade that sent shares of Keryx Pharmaceuticals soaring 30% over the last couple of trading sessions. After handing back perifosine to its partner Aeterna Zentaris, Keryx is regaining momentum after a successful phase 3 trial of its other drug candidate, Zerenex. To find out whether this newfound bullish sentiment is deserved, watch the video and Fool On.
Keryx may be too risky to become one of the many dynamic recommendations made to Motley Fool Rule Breakers subscribers, but now's a great time to discover the next rule-breaking multibagger that the newsletter has unearthed. It's a free report. Want it? Get it.
